文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期，新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

一种联合使用选择性5-羟色胺再摄取抑制剂（SSRIs）和甘丙肽N端片段（1-15）治疗抑郁症的新增强策略。

A New Augmentation Strategy against Depression Combining SSRIs and the N-terminal Fragment of Galanin (1-15).

作者信息

Flores-Burgess Antonio, Millon Carmelo, Cantero-Garcia Noelia, Pineda-Gomez Juan Pedro, Flores-Gomez Marta, Diaz-Cabiale Zaida

机构信息

Departamento de Fisiología, Facultad de Medicina, Universidad de Málaga, Campus de Teatinos s/n. 29080 Málaga, Spain.

出版信息

Curr Neuropharmacol. 2025;23(3):295-309. doi: 10.2174/1570159X23666241003125019.

DOI:10.2174/1570159X23666241003125019
PMID:39484753
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11808584/
Abstract

Depression is one of the most disabling mental disorders, with the second highest social burden; its prevalence has grown by more than 27% in recent years, affecting 246 million in 2021. Despite the wide range of antidepressants available, more than 50% of patients show treatment-resistant depression. In this review, we summarized the progress in developing a new augmentation strategy based on combining the N-terminal fragment of Galanin (1-15) and SSRI-type antidepressants in animal models.

摘要

抑郁症是最具致残性的精神障碍之一，社会负担位居第二；近年来其患病率增长超过27%，2021年有2.46亿人受其影响。尽管有多种抗抑郁药可供使用，但超过50%的患者表现出难治性抑郁症。在本综述中，我们总结了在动物模型中基于联合甘丙肽N端片段（1-15）和SSRI类抗抑郁药开发新的增效策略的进展。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1ce9/11808584/59ee791f8169/CN-23-3-295_F3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1ce9/11808584/eddfaa80a542/CN-23-3-295_F1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1ce9/11808584/9350ec92b0b3/CN-23-3-295_F2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1ce9/11808584/59ee791f8169/CN-23-3-295_F3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1ce9/11808584/eddfaa80a542/CN-23-3-295_F1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1ce9/11808584/9350ec92b0b3/CN-23-3-295_F2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1ce9/11808584/59ee791f8169/CN-23-3-295_F3.jpg

相似文献

[1]
A New Augmentation Strategy against Depression Combining SSRIs and the N-terminal Fragment of Galanin (1-15).

Curr Neuropharmacol. 2025

[2]
Galanin (1-15) enhancement of the behavioral effects of Fluoxetine in the forced swimming test gives a new therapeutic strategy against depression.

Neuropharmacology. 2017-5-15

[3]
Combining mirtazapine with SSRIs or SNRIs for treatment-resistant depression: the MIR RCT.

Health Technol Assess. 2018-11

[4]
Risk of suicidality in depression with serotonergic antidepressants.

Ann Clin Psychiatry. 2000-3

[5]
Selective serotonin reuptake inhibitor (SSRI) use during pregnancy and risk of preterm birth: a systematic review and meta-analysis.

BJOG. 2016-11

[6]
[SSRI resistant depression. Supplementation with noradrenergic pharmaceuticals can be a good alternative].

Lakartidningen. 2004-9-2

[7]
WITHDRAWN: Selective serotonin reuptake inhibitors (SSRIs) versus other antidepressants for depression.

Cochrane Database Syst Rev. 2007-7-18

[8]
Treatment of antidepressant nonresponders: augmentation or switch?

J Clin Psychiatry. 1998

[9]
Use of selective serotonin-reuptake inhibitors in the treatment of depression in adults with HIV.

Ann Pharmacother. 2005-1

[10]
Lithium or an atypical antipsychotic drug in the management of treatment-resistant depression: a systematic review and economic evaluation.

Health Technol Assess. 2013-11

本文引用的文献

[1]
Galanin N-terminal fragment (1-15) reduces alcohol seeking and alcohol relapse in rats: Involvement of mesocorticolimbic system.

Biomed Pharmacother. 2022-9

[2]
Dysregulation of adult hippocampal neuroplasticity in major depression: pathogenesis and therapeutic implications.

Mol Psychiatry. 2022-6

[3]
The Combination of Galanin (1-15) and Escitalopram in Rats Suggests a New Strategy for Alcohol Use Disorder Comorbidity with Depression.

Biomedicines. 2022-2-9

[4]
Galanin (1-15) Enhances the Behavioral Effects of Fluoxetine in the Olfactory Bulbectomy Rat, Suggesting a New Augmentation Strategy in Depression.

Int J Neuropsychopharmacol. 2022-4-19

[5]
Exploring the role of neuropeptides in depression and anxiety.

Prog Neuropsychopharmacol Biol Psychiatry. 2022-3-2

[6]
HPA Axis in the Pathomechanism of Depression and Schizophrenia: New Therapeutic Strategies Based on Its Participation.

Brain Sci. 2021-9-30

[7]
Galanin(1-15) Potentiates the Antidepressant-like Effects Induced by Escitalopram in a Rat Model of Depression.

Int J Mol Sci. 2021-10-7

[8]
Global prevalence and burden of depressive and anxiety disorders in 204 countries and territories in 2020 due to the COVID-19 pandemic.

Lancet. 2021-11-6

[9]
Predictors of Quality of Life Improvement with Escitalopram and Adjunctive Aripiprazole in Patients with Major Depressive Disorder: A CAN-BIND Study Report.

CNS Drugs. 2021-4

[10]
Efficacy of Buspirone Augmentation of Escitalopram in Patients with Major Depressive Disorder with and without Atypical Features: A Randomized, 8 Week, Multicenter, Open-Label Clinical Trial.

Psychiatry Investig. 2020-8

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索